0:00
/
0:00

Paid episode

The full episode is only available to paid subscribers of Antifragile Thinking

Piramal Pharma: Why and When?

22

Table of contents

  1. CDMO Growth Champion and Challenger

  2. Basket of Growth Plus US Presence

  3. Intrinsic ROCE vs Reported ROCE

  4. ROC ‘As Is’ versus ROC ‘To Be’

  5. US Gross and EBITDA Margins

  6. Conservative Investors Sle…

Listen to this episode with a 7-day free trial

Subscribe to Antifragile Thinking to listen to this post and get 7 days of free access to the full post archives.